One of the most touted pharmaceutical duos since the pandemic started – Pfizer/BioNTech – released news about the immune response of their COVID-19 vaccine for 5–11-year-old volunteers
The two companies revealed the vaccine generated a robust immune response in their Phase II/III clinical trial. The latest results matched those observed in 16-to-25-year-olds. Albert Bourla, Pfizer Chief Executive, stated: "These trial results provide a strong foundation for seeking authorization of our vaccine for children 5 to 11 years old, and we plan to submit them to the FDA and other regulators with urgency."
Following the promising results, Pfizer/BioNTech are planning to ask for authorization as soon as possible for their vaccine to be administrated to children in that age range in the US, Europe, and elsewhere. A rapid approval could help mitigate a potential increase of cases in the fall, given that schools are starting to reopen nationwide.
The companies are looking forward to data on how the vaccine performs on children 2-to-5 years of age and six months to 2 years old as soon as Q4 2021.
Sources: barrons.com, reuters.com
Users/readers should not rely solely on the information presented herewith and should do their own research/analysis by also reading the actual underlying research. The content herewith is generic and does not take into consideration individual personal circumstances, investment experience or current financial situation.
Key Way Markets Ltd shall not accept any responsibility for any losses of traders due to the use and the content of the information presented herein. Past performance and forecasts are not reliable indicators of future results.